Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salmeterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 18/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 17/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | FPR3 | P25089 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salmeterol SCHEMBL4767 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL4768 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL4452108 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL29397921 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL4450046 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL7176067 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL28889602 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL29266779 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL6152211 | 0.98 | ADRB2 (0.96) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL4454918 | 0.98 | ADRB2 (0.96) | ADRB2ADRB1ADRB3KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4456890-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT Pharma Co., Ltd (KR) | 2024-11-06 | — | — | EP | claimed |
| EP-4329849-A1 | INHALER | 3D Engineering Design Limited (GB) | 2024-03-06 | — | — | EP | claimed |
| WO-2023156808-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-08-24 | — | — | WO | claimed |
| EP-4106722-A1 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | Chiesi Farmaceutici S.p.A. (IT) | 2022-12-28 | — | — | EP | claimed |
| WO-2022229665-A1 | INHALER | 3D Engineering Design Limited (GB) | 2022-11-03 | — | — | WO | claimed |
| US-12616690-B2 | Specific AKT3 activator and uses thereof | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250368949-A1 | SYSTEMS AND METHODS FOR GROWING CELLS IN VITRO | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2025-12-04 | — | — | US | disclosed |
| EP-4653429-A1 | SPECIFIC AKT3 ACTIVATOR AND USES THEREOF | Augusta University Research Institute, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-3911302-B1 | DRUG DELIVERY SYSTEMS CONTAINING OXIDIZED CHOLESTEROLS | GEORGIA TECH RES INST (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4329849-B1 | INHALER | 3D ENGINEERING DESIGN LTD (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-3678666-B1 | SPECIFIC AKT3 ACTIVATOR AND USES THEREOF | UNIV RES INST INC AUGUSTA (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025137236-A1 | COMPOSITIONS AND METHODS FOR MODULATING CDCP1 MEDIATED SIGNAL TRANSDUCTION | NEXTCURE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2022128850-A1 | NOVEL ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-06-23 | — | — | WO | disclosed |
| EP-3999184-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT Pty Limited (AU) | 2022-05-25 | — | — | EP | disclosed |
| CN-111053761-B | Bisphosphonic acid medicine for inhalation, preparation method thereof and application thereof in chronic obstructive pulmonary disease | 杭州旦承医药科技有限公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-3986899-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022081814-A1 | INHALABLE CANNABINOID FORMULATIONS | OGBURN MICHAEL (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11291719-B2 | Methods and compositions for modulating Akt3 | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| WO-2022039850-A1 | TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS | VYNE THERAPEUTICS INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022035692-A1 | METHODS AND COMPOSITIONS FOR MODULATING AKT3 | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616690-B2 | Specific AKT3 activator and uses thereof | AKT3, AKT2, PIK3C2B | ADRB2 2583/4885ADRB1 2500/4885ADRB3 416/4885 |
| US-11291719-B2 | Methods and compositions for modulating Akt3 | AKT3, PTEN, AKT2 | ADRB2 3839/4885ADRB1 3523/4885ADRB3 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.